Evaluation of the effects of nicotineamide mononucleotide administered intravenously to healthy subjects.

Evaluation of the effects of nicotineamide mononucleotide administered intravenously to healthy subjects. - Evaluation of the effects of nicotineamide mononucleotide administered intravenously to healthy subjects.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049123

Enrollment

Registered

2022-10-11

Start date

2022-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

Intravenous administration of NMN

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healhty men and women over 20 years old

Exclusion criteria

Exclusion criteria: (1) The subjects who suffer from serious cerebrovascular, cardiac, metabolic, hepatic, renal, gastrointestinal, or cancer diseases (2) The subjects who habe an extremely irregular diet (3) The subjects with serious allegic diseases (4) Pregnant or possibly pregnant (5) The subject who are currently participating in other clinical research or clinical trials, or those who habe participated in other clinical research or clinicl trals within the past three months (6) The subjects who are judged as unsuitable for the study by the principal investigator or subinvestigator (7) The subjects who lack judgment

Design outcomes

Primary

Measure	Time frame
Safety of intravenous administration of NMN.	—

Countries

Japan

Contacts

Public ContactYuji Suzuki

TOKYO GINZA WELLNESS & AGING CLINIC Clinical Research Office

y.suzuki@tgwaclinic.com03-6263-2034

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026